drugset / Trial / NCT05524389
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
Phase 3
Not yet recruiting
624 enrolled
Peking Union Medical College Hospital
940 Hospital of the People's Liberation Army Joint Logistic Support Force · collabCancer Institute and Hospital, Chinese Academy of Medical Sciences · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabPeking University First Hospital · collabSecond Hospital of Jilin University · collabThe Affiliated Hospital of Inner Mongolia Medical University · collabThe First Affiliated Hospital of Air Force Medicial University · collabThe Second Affiliated Hospital of Dalian Medical University · collabThird Affiliated Hospital of Xinjiang Medical University · collabXiangya Hospital of Central South University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy and toxicity of early stage endometrial cancer based on molecular classification and conventional risk stratification adjuvant therapy decision-making, and to provide high-quality evidence-based medical evidence for individualized adjuvant therapy selection under the guidance of fine stratification system of endometrial cancer.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2026-12-01
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |